AbbVie Inc. (NYSE:ABBV) Short Interest Update

AbbVie Inc. (NYSE:ABBV) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 20,125,180 shares, a decline of 19.9% from the March 15th total of 25,110,220 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 8,202,339 shares, the short-interest ratio is presently 2.5 days.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New clinical catalysts — AbbVie’s Phase 4 head‑to‑head psoriasis study could create a meaningful commercial catalyst if results favor its therapy, supporting upside expectations for market share and pricing power. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: Pipeline expansion into obesity — AbbVie launched a Phase 1 trial for ABBV‑295, signaling R&D diversification beyond immunology and potential long‑term upside if early data show promise. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: Real‑world HCV data could shore up legacy franchise value — retrospective safety/efficacy analyses for Glecaprevir/Pibrentasvir may support prescribing and lifecycle value. AbbVie’s Real‑World HCV Study: What G/P Safety Data Could Mean for ABBV Investors
• Positive Sentiment: Value/dividend thesis — bullish retail/analyst pieces argue AbbVie’s strong dividend yield, cash flows, and durable immunology franchises make it attractive to buy on weakness. This supports demand from income-oriented investors. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: Commercial momentum for Skyrizi and Rinvoq — coverage notes strong sales growth for these franchises, which underpins revenue trajectory and offsets some concerns about valuation and technical weakness. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
• Neutral Sentiment: Market opportunity context — reports on the Middle East & Africa biosimilars market list AbbVie among players; this highlights long‑term opportunity and competitive pressures from biosimilars but is not an immediate stock mover. Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, …
• Neutral Sentiment: Sector reports (thyroid eye disease) and comparisons to peers — market analyses and a Pfizer vs. AbbVie piece provide framing on relative strengths and risks but add mixed conclusions rather than a clear near-term catalyst. Thyroid Eye Disease Treatment Market Research Report 2026 Featuring Amgen, … AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit
• Negative Sentiment: Technical pressure — multiple outlets highlight ABBV trading below its 50‑ and 200‑day moving averages, a short‑term bearish signal that can trigger further selling by technical traders and funds. That is likely the primary driver of today’s downward price move. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Evercore reduced their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a report on Tuesday, January 20th. Finally, Morgan Stanley lifted their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.00.

AbbVie Trading Down 0.3%

NYSE ABBV traded down $0.71 during trading on Friday, reaching $208.29. The company’s stock had a trading volume of 8,981,356 shares, compared to its average volume of 6,917,997. The firm has a market capitalization of $368.28 billion, a price-to-earnings ratio of 88.26, a price-to-earnings-growth ratio of 0.74 and a beta of 0.38. AbbVie has a 12 month low of $168.54 and a 12 month high of $244.81. The firm has a 50 day moving average price of $219.00 and a 200 day moving average price of $223.57.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s payout ratio is currently 293.22%.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by insiders.

Institutional Trading of AbbVie

A number of institutional investors have recently bought and sold shares of ABBV. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the 3rd quarter worth approximately $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth approximately $28,000. Westend Capital Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth approximately $29,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie during the 3rd quarter worth approximately $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.